Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering
- TEL AVIV, Israel , July 14, 2023 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, announced today that it has entered into securities purchase agreements with two institutional investors to purchase 5,600,000 of its ordinary shares (or pre-funded warrants in lieu thereof) and warrants to purchase 5,600,000 ordinary shares at a combined purchase price of $1.25 per ordinary share and accompanying warrant (the "Offering").
- 07/14/2023
|
Why Is Galmed Pharmaceuticals (GLMD) Stock Moving Today?
- Galmed Pharmaceuticals (NASDAQ: GLMD ) stock is on the move Thursday after the company priced a public offering of its shares. Galmed Pharmaceuticals intends to offer up 6,578,947 shares of GLMD stock at a price of $2.28 per share.
- 07/13/2023
|
Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC
- OnKai's AI models redefine the methodologies and economics of clinical trials TEL AVIV, Israel , July 10, 2023 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, is delighted to announce the first step in its strategic partnership with OnKai, where OnKai will apply its artificial intelligence (AI), models for enrollment and execution of clinical trials in underserved communities, starting with Galmed's innovative Primary Sclerosing Cholangitis (PSC) clinical development program.
- 07/10/2023
|
Why Is Galmed Pharmaceuticals (GLMD) Stock Up 37% Today?
- Galmed Pharmaceuticals (NASDAQ: GLMD ) stock is gaining on Friday after the company announced an investment agreement with OnKai . That agreement has Galmed Pharmaceuticals making a $1.5 million equity investment in OnKai.
- 05/05/2023
|
Galmed Pharmaceuticals (GLMD) Moves to Buy: Rationale Behind the Upgrade
- Galmed Pharmaceuticals (GLMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 09/14/2022
|
Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q4 2021 Results - Earnings Call Transcript
- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD ) Q4 2021 Earnings Conference Call May 2, 2022 8:30 AM ET Company Participants Allen Baharaff - President and CEO Yohai Stenzler - Chief Accounting Officer Conference Call Participants Steven Seedhouse - Raymond James Kristen Kluska - Cantor Fitzgerald Naz Rahman - Maxim Group Operator Good day and welcome to the Galmed Conference Call to discuss Financial Results for the Fourth Quarter and Year-end 2021.
- 05/02/2022
|
Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q3 2021 Results - Earnings Call Transcript
- Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q3 2021 Results - Earnings Call Transcript
- 11/08/2021
|
Galmed's Anti-Inflammatory Compound Shows Encouraging Preclinical Action
- Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) has announced the data publication for its preclinical compound, Amilo-5MER, in the Journal of Autoimmunity. Amilo-5MER is a five amino acid in a specific sequence originally isolated from synovial fluid of rheumatoid arthritis patients.
- 08/19/2021
|
Galmed Pharmaceuticals Announces Publication in "The Journal of Autoimmunity" for its IND ready, Amilo-5MER, a specific anti-inflammatory compound
- TEL AVIV, Israel, Aug. 19, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today the publication in The Journal of Autoimmunity for its IND ready compound, Amilo-5MER entitled: "MTADV 5-MER peptide suppresses chronic inflammations as well as autoimmune pathologies and unveils a new potential target-Serum Amyloid A.
- 08/19/2021
|
Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q2 2021 Results - Earnings Call Transcript
- Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q2 2021 Results - Earnings Call Transcript
- 08/09/2021
|
GLMD Stock Increases Over 4% Pre-Market: Why It Happened
- The stock price of Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) increased by over 4% pre-market. This is why it happened.
- 08/02/2021
|
FDA Agrees with Galmed's Plan to use Aramchol Meglumine in the Randomized Double-Blind Placebo-Controlled Part of the Phase 3 ARMOR study
- TEL AVIV, Israel, Aug. 2, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today that the FDA agreed with its plan to use Aramchol meglumine (in lieu of Aramchol free acid) in its Phase 3 ARMOR study without the need to conduct additional nonclinical and clinical studies other than planned limited pharmacology studies relating to Aramchol meglumine.
- 08/02/2021
|
Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q1 2021 Results - Earnings Call Transcript
- Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q1 2021 Results - Earnings Call Transcript
- 05/13/2021
|
Galmed Pharmaceuticals Provides Business Updates and Reports First Quarter 2021 Financial Results
- TEL AVIV, Israel, May 13, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, an oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH and fibrosis, reports financial results for the three months ended March 31, 2021.
- 05/13/2021
|
Week In Review: WHO Close To Approving Global Use For 2 China COVID-19 Vaccines
- The WHO approved Sinopharm's COVID-19 vaccine for emergency use, which will give poorer nations access to a vaccine against the global pandemic. CoronaVac is the first China-developed COVID-19 vaccine under consideration in Europe, joining vaccines from CureVac, Novavax and a Russian vaccine, Sputnik V.
- 05/10/2021
|
Galmed Pharmaceuticals to Report First Quarter 2021 Financial Results and Provide Business Update on Thursday May 13
- TEL AVIV, Israel, May 6, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in Phase 3 clinical trial for the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis announced today that it will host a conference call and webcast on Thursday, May 13, 2021, to provide an update on current developments with respect to its clinical programs for Aramchol™ and to discuss financial results for the quarter ended March 31, 2021.
- 05/06/2021
|
Galmed Announces Approval of IND Application in China for Aramchol for the Treatment of NASH & Fibrosis in the Global Phase 3 ARMOR Registrational Study
- TEL AVIV, Israel, May 3, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today that the National Medical Products Administration (NMPA) has granted approval for the Investigational New Drug (IND) application for Galmed's Phase 3 ARMOR registrational study of Aramchol for the treatment of NASH & Fibrosis.
- 05/03/2021
|
GLMD Stock Price Increased 14.62%: Why It Happened
- The stock price of Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) has increased by 14.62% on March 19. This is why it happened.
- 03/22/2021
|
Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q4 2020 Results - Earnings Call Transcript
- Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q4 2020 Results - Earnings Call Transcript
- 03/18/2021
|
Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2020 Financial Results
- TEL AVIV, Israel, March 18, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, an oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH and fibrosis, reports financial results for the three and twelve months ended December 31, 2020.
- 03/18/2021
|
Galmed Pharmaceuticals Announces Dosing of First Subject in First in Human Phase 1 Trial of Amilo-5MER
- TEL AVIV, Israel, March 16, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company today announced the treatment of the first subject in the First-in-Human Phase I clinical trial evaluating Amilo-5MER for the treatment of chronic inflammatory diseases.
- 03/16/2021
|
Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2020 Financial Results and Provide Business Update on Thursday March 18
- TEL AVIV, Israel, March 11, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in Phase 3 clinical trial for the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis announced today that it will host a conference call and webcast on Thursday, March 18, 2021, to provide an update on current developments with respect to its clinical programs for Aramchol™ and to discuss financial results for the quarter and year ended December 31, 2020.
- 03/11/2021
|
Galmed to add Open Label Part to ARMOR Study; First Read-out Expected in Q4 2021
- TEL AVIV, Israel, Dec. 17, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today the addition of an open-label part to its ARMOR Phase 3...
- 12/17/2020
|
Week In Review: Baidu Raising $2 Billion For New China Biopharma
- Baidu, one of China's major internet/AI companies, is talking with investors about raising $2 billion to fund a new China drug development and diagnostics company.
- 09/13/2020
|
Viking Therapeutics: Another Year In Review
- Recently announced Q2'20 financial results and provided key updates on development timelines. Filed IND for VK0214 in X-ALD.
- 08/13/2020
|
Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results
- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, an oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH and fibrosis, provides today updated information on the Company's scientific and clinical development programs and reports financial results for the three and six months ended June 30, 2020. The Company will host a conference call and webcast at 08:30 ET today.
- 08/06/2020
|
Galmed Pharmaceuticals Announces Acceleration of its New Clinical Amilo-5MER program
- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases provides today updated information on the Company's pipeline program.
- 08/06/2020
|
Galmed Pharmaceuticals to Report Second Quarter 2020 Financial Results and Provide Business Update on Thursday August 6
- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in a Phase 3 clinical trial for the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis announced today that it will host a conference call and webcast on Thursday, August 6, 2020, to provide an update on current developments with respect to its clinical programs for Aramchol™ and to discuss financial results for the three and six months ended June 30, 2020.
- 07/30/2020
|
How Is Galmed Pharmaceuticals' (NASDAQ:GLMD) CEO Paid Relative To Peers?
- This article will reflect on the compensation paid to Allen Baharaff who has served as CEO of Galmed Pharmaceuticals...
- 07/22/2020
|
3 Healthcare Stocks Under $5 With Triple-Digit Upside Potential
- On Wall Street, some things never change. Public health crisis or not, the fact of the matter remains that healthcare stocks are the epitome of risk/reward plays. Why? It comes down to the nature of the industry itself. Healthcare companies are unique in that their financial performances aren’t necessarily the most important piece of the puzzle. Rather, a few key factors like clinical data readouts or regulatory approvals indicate whether or not a particular name will be able to generate sustainable revenues in the long run. As such, any development, good or bad, can act as a catalyst that launches shares in either direct. So, which strategy can help investors find the healthcare stocks poised to blast off on an upward trajectory? One approach is to follow the pros on Wall Street.We used TipRanks’ database to lock in on three healthcare stocks that have been given the Street’s blessing, and come with an affordable price tag. Each ticker trades for less than $5 per share and has earned a “Strong Buy” consensus rating from the analyst community. The icing on the cake? Serious upside potential is on the table. Galmed Pharmaceuticals (GLMD)Focused on the development of its product candidate, Aramchol, Galmed Pharmaceuticals wants to provide patients with a more effective therapy for the treatment of Non-alcoholic Steatohepatitis (NASH). Given its recent addition to its product lineup and its $4.50 share price, the healthcare name is scoring major points with the Street.Back in May, GLMD unveiled Aramchol meglumine, which is an Aramchol salt version that is more soluble than the free acid version, with it also showing improved PK characteristics. The therapy is eligible for New Chemical Entity (NCE) designation and additional patent protection.Weighing in on the impact of this revamp, five-star analyst Yasmeen Rahimi calls the candidate GLMD’s “new star," arguing it “can raise the bar for Aramchol's efficacy in NASH and potentially add a layer of patent protection.” The analyst points out that the company has already placed a significant focus on protecting its intellectual property, with patents maintained in 37 territories in the EU, as well as other countries including Canada, Australia, China and Japan. In addition, patent discussions are taking place in the U.S.Speaking to the improved PK characteristics, Rahimi highlights that when compared to the Aramchol free acid version, Aramchol meglumine produced nearly identical AUCs following a single dose, but a higher AUC after multiple doses, and Meglumine had an identical half-life at both the single and multiple doses. “Importantly, Aramchol meglumine demonstrated three-fold lower variation in concentration during multiple dosing, which hints at a potential for more steady concentrations in patients treated with meglumine and Aramchol meglumine's Cmax was higher during multiple dosing or steady state administration,” the analyst added.As for how COVID-19 affects this trial, Rahimi told clients “GLMD is taking a diligent approach to maintaining execution of Phase 3 ARMOR.” These efforts include temporarily halting the screening of new patients into ARMOR to minimize potential COVID-19 exposure, taking this time to advance the opening of new sites in preparation for when screening and randomization is possible and reducing its costs.To this end, Rahimi rates GLMD a Buy, along with a $33 price target. This figure conveys her confidence in GLMD’s ability to soar 622% in the next twelve months. (To watch Rahimi’s track record, click here)Turning now to the rest of the Street, other analysts also like what they’re seeing. 6 Buys and a single Hold add up to a Strong Buy consensus rating. Given the $19.86 average price target, the upside potential comes in at 334%. (See GLMD stock analysis on TipRanks)ImmunoGen (IMGN)Utilizing antibody-drug conjugates, or ADCs, ImmunoGen hopes its therapies will be able to disrupt the progression of cancer. Ahead of key data readouts, several members of the Street believe that at $4.22, its share price reflects an attractive entry point.Pointing to the FORWARD II study, five-star analyst John Newman, of Canaccord, tells clients that its mirvetuximab asset, which was evaluated in combination with Avastin, generated encouraging results. In addition to exhibiting strong efficacy and safety, a 64% Overall Response Rate (ORR) among Folate Receptor alpha high platinum agnostic patients was witnessed.Newman also noted, “Importantly, mirvetuximab + Avastin demonstrated a 59% ORR for FRa high patients that were platinum resistant, comparing well to ~27-28% for bevacizumab + chemotherapy in a similar population. In addition, ORR was similar between platinum-resistant and platinum-sensitive patients (59% vs 69%), suggesting encouraging efficacy for mirvetuximab in both populations.”As for what these results mean, Newman argues that they suggest mirvetuximab will eventually be approved and used in all lines of ovarian cancer, underscoring the importance of its safety in combination with other drugs.Going forward, enrollment for the Phase 3 MIRASOL trial and Phase 2 SORAYA trial is underway, with top-line data for SORAYA still slated for release in mid-2021. This will be followed up by MIRASOL’s top-line data readout in the first half of 2022.“Importantly, mirvetuximab is known to be a highly active agent in ovarian cancer, which should support robust enrollment. Also, we remind investors that the FORWARD I trial enrolled ahead of schedule in 9 months. We recognize that the COVID-19 pandemic may have some effect on clinical trial enrollment, but we believe the effects can be mitigated,” Newman commented.The analyst is expecting positive data from both trials, with the Phase 2 data potentially supporting accelerated approval and the Phase 3 results supporting full approval. “Importantly, we see multi-leg long-term growth potential for mirvetuximab in ovarian cancer based on expansion into earlier lines of therapy, and eventual combination with platinum therapy in the front-line setting,” he stated.Everything that IMGN has going for it prompted Newman to leave a Buy rating and $12 price target on the stock. Should the target be met, a twelve-month gain of 183% could be in store. (To watch Newman’s track record, click here) Do other analysts agree with Newman? They do. Only Buy ratings, 3, in fact, have been issued in the last three months. At $10.50, the average price target puts the upside potential at 147%. (See ImmunoGen stock analysis on TipRanks)Matinas BioPharma (MTNB)The last healthcare stock on our list, Matinas BioPharma, brings cutting-edge technology to the table, with the goal of developing therapies capable of overcoming the limitations associated with existing options. Even though COVID-19 impacted its clinical activity, multiple analysts believe that its $0.72 share price presents investors with a unique buying opportunity.As a result of the pandemic, the trials for MTNB’s two leading programs, MAT9001 and MAT2203, were delayed. That said, management recently stated it plans to restart the enrollment of ENHANCE-IT for MAT9001 and EnACT for MAT2203. Writing for BTIG, five-star analyst Robert Hazlett noted, “These two programs, especially MAT9001, are core value drivers for Matinas, and trial progress is welcome news.”Looking more closely at the trials, ENHANCE-IT is a head-to-head open-label, 28-day crossover trial featuring patients with elevated triglycerides designed to assess the pharmacodynamic (PD) effects of MAT9001 compared to Amarin’s Vascepa. Hazlett points out that the company has added two additional clinical sites to the program to compensate for the delay.Speaking to the strength of its MAT9001 asset, Hazlett believes the fact that its composition includes DPA, a more potent TG lowering Omega-3, sets it apart from the competition. In addition, the therapy doesn’t increase LDL, with it able to achieve substantially higher blood levels of EPA than Vascepa. “MAT9001’s positioning as a more potent, yet differentiated EPA-based omega 3 has become even more important under the lens of recent Vascepa patent trial challenge... We believe ENHANCE-IT can further differentiate MAT9001, and project material potential for this program, with estimate peak revenue of greater than $1.5 billion,” Hazlett said.As for EnACT, it is an open-label, sequential cohort study evaluating MAT2203, its liposomal nanocrystal (LNC) technology candidate which allows for oral delivery of the potent anti-fungal amphotericin B. It was designed for the treatment of HIV patients with cryptococcal meningitis. “Cryptococcal meningitis represents a beachhead for broader antifungal consideration of MAT2203 over time,” Hazlett commented. It should be noted that the CF Foundation has supported the therapy’s preclinical development, and MTNB has submitted a proposal to receive funding for MAT2501 through Phase 2.To this end, Hazlett rates MTNB a Buy along with a $5 price target. Shares could appreciate by 586%, should the analyst’s thesis play out in the coming months. (To watch Hazlett’s track record, click here) Looking at the consensus breakdown, the rest of the Street agrees with Hazlett’s assessment. With 6 Buys and no Holds or Sells, the word on the Street is that MTNB is a Strong Buy. The $3.29 average price target implies shares could skyrocket 362% in the next year. (See MTNB stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
- 07/14/2020
|
Here is What Hedge Funds Think About Galmed Pharmaceuticals Ltd (GLMD)
- At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each stock might be going. […]
- 07/06/2020
|
Inventiva SA Starts U.S. IPO Rollout
- Inventiva SA has filed to raise $90 million in a U.S. IPO. The firm is advancing a pipeline of treatment candidates for NASH, MPS and other diseases. IVA is pre
- 06/26/2020
|
How Galmed (GLMD) Stock Stands Out in a Strong Industry
- Galmed (GLMD) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- 06/10/2020
|
Benzinga's Top Upgrades, Downgrades For May 22, 2020
|
B. Riley FBR Downgrades Galmed Pharmaceuticals to Neutral, Lowers Price Target of $8
|
61 Biggest Movers From Yesterday
|
Raymond James Maintains Outperform on Galmed Pharmaceuticals, Lowers Price Target to $20
|
Edited Transcript of GLMD earnings conference call or presentation 14-May-20 12:30pm GMT
- Q1 2020 Galmed Pharmaceuticals Ltd Earnings Call
- 05/15/2020
|
After Drug Failure, Genfit's Cupboard Is Nearly Bare
- Company’s high hopes for NASH drug stymied, providing opening for Intercept Pharma treatment Continue reading...
- 05/14/2020
|
The Daily Biotech Pulse: ASCO Abstracts Create Stock Ripples, Applied DNA's Coronavirus Test Receives EUA, Biopharmx Shareholders Vet Reverse Merger
|
Galmed Pharmaceuticals Q1 EPS $(0.290) Beats $(0.370) Estimate
|
Galmed Pharmaceuticals Provides Business Update and Reports First Quarter 2020 Financial Results
- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, an oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH and fibrosis, provides today updated information on the Company's clinical development program and reports financial results for the three months ended March 31, 2020. The Company will host a conference call and webcast at 08:30 ET today.
- 05/14/2020
|
After Drug Failure, Genfit's Cupboard Is Nearly Bare
|
The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight
- The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB)...
- 05/10/2020
|
Galmed Pharmaceuticals to Report First Quarter 2020 Financial Results and Provide Business Update on Thursday May 14
- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in Phase 3 clinical trial for the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis announced today that it will host a conference call and webcast on Thursday, May 14, 2020, to provide an update on current developments with respect to its clinical programs for Aramchol™ and to discuss financial results for the quarter ended March 31, 2020.
- 05/07/2020
|
Such Is Life: How Galmed Pharmaceuticals (NASDAQ:GLMD) Shareholders Saw Their Shares Drop 54%
- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) shareholders should be happy to see the share price up 25% in the last...
- 05/02/2020
|
Analysts Have Conflicting Sentiments on These Healthcare Companies: Teladoc (TDOC), LivaNova (LIVN) and Theratechnologies (THTX)
- Analysts have been eager to weigh in on the Healthcare sector with new ratings on Teladoc (TDOC), LivaNova (LIVN) and Theratechnologies (THTX). Teladoc
- 04/30/2020
|
Analysts Have Conflicting Sentiments on These Healthcare Companies: Teladoc (NYSE: TDOC), LivaNova (NASDAQ: LIVN) and Theratechnologies (NASDAQ: THTX)
- Analysts have been eager to weigh in on the Healthcare sector with new ratings on Teladoc (TDOC – Research Report),
- 04/30/2020
|
Analysts Are Bullish on These Healthcare Stocks: Madrigal Pharmaceuticals (MDGL), NuVasive (NUVA)
- There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Madrigal Pharmaceuticals (MDGL) and NuVasive (NUVA) with
- 04/15/2020
|
Analysts Are Bullish on These Healthcare Stocks: Madrigal Pharmaceuticals (MDGL), NuVasive (NUVA)
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Madrigal Pharmaceuticals
- 04/15/2020
|
Analysts' Opinions Are Mixed on These Healthcare Stocks: Akero Therapeutics (AKRO), Shockwave Medical (SWAV) and VBI Vaccines (VBIV)
- Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Akero Therapeutics (AKRO), Shockwave Medical (SWAV) and
- 04/01/2020
|
Edited Transcript of GLMD earnings conference call or presentation 12-Mar-20 12:30pm GMT
- Q4 2019 Galmed Pharmaceuticals Ltd Earnings Call
- 03/27/2020
|
The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company
- Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 19.) Biomerica, Inc. (NASDAQ: BMRA ) Centogene NV (NASDAQ: CNTG ) Gilead Sciences, Inc. (NASDAQ: GILD ) Imara Inc (NASDAQ: IMRA ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Down In The Dumps (Biotech stocks that hit 52-week lows March 19.) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) Acer Therapeutics Inc (NASDAQ: ACER ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Aikido Pharma Inc (NASDAQ: AIKI ) Alpine Immune Sciences Inc (NASDAQ: ALPN ) Amphastar Pharmaceuticals Inc (NASDAQ: AMPH ) Anika Therapeutics Inc (NASDAQ: ANIK ) Anixa Biosciences Inc (NASDAQ: ANIX ) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Antares Pharma Inc (NASDAQ: ATRS ) Apyx Medical Corp (NASDAQ: APYX ) Arca Biopharma Inc (NASDAQ: ABIO ) Aridis Pharmaceuticals Inc (NASDAQ: ARDS ) aTyr Pharma Inc (NASDAQ: LIFE ) AVEO Pharmaceuticals, Inc.
- 03/20/2020
|
Stocks That Hit 52-Week Lows On Thursday
- On Thursday morning, 1178 companies hit new 52-week lows.
Facts of Interest:
The largest company by market cap to set a new 52-week low was Nuveen Preferred & Income...
- 03/19/2020
|
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) Biomerica, Inc. (NASDAQ: BMRA )( announced commencement of international shipment of rapid COVID-19 test) BioNTech SE – ADR (NASDAQ: BNTX ) Imara Inc (NASDAQ: IMRA ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 18) 89bio Inc (NASDAQ: ETNB ) AC Immune SA (NASDAQ: ACIU ) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADM ) Adial Pharmaceuticals Inc (NASDAQ: ADIL ) ADMA Biologics Inc (NASDAQ: ADMA ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Agenus Inc (NASDAQ: AGEN ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Aikido Pharma Inc (NASDAQ: AIKI ) Akorn, Inc. (NASDAQ: AKRX ) Alkermes Plc (NASDAQ: ALKS ) Allogene Therapeutics Inc (NASDAQ: ALLO ) Alterity Therapeutics Ltd (NASDAQ: ATHE ) AMAG Pharmaceuticals, Inc.
- 03/19/2020
|
Analysts Offer Insights on Healthcare Companies: Akero Therapeutics (AKRO) and Blueprint Medicines (BPMC)
- There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Akero Therapeutics (AKRO) and Blueprint Medicines (BPMC)
- 03/18/2020
|
Analysts Offer Insights on Healthcare Companies: Akero Therapeutics (NASDAQ: AKRO) and Blueprint Medicines (NASDAQ: BPMC)
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Akero Therapeutics (
AKRO
–
Research Report
) and Blueprint Medicines (
BPMC
–
Research Report
) with bullish sentiments.
Akero Therapeutics (AKRO)
Canacco
- 03/18/2020
|
B.Riley FBR Maintains Their Buy Rating on Galmed Pharmaceuticals (GLMD)
- B.Riley FBR analyst Mayank Mamtani maintained a Buy rating on Galmed Pharmaceuticals (GLMD) on March 13 and set a price target of $11.00. The company's
- 03/16/2020
|
B.Riley FBR Maintains Their Buy Rating on Galmed Pharmaceuticals (GLMD)
- B.Riley FBR analyst Mayank Mamtani maintained a Buy rating on Galmed Pharmaceuticals (GLMD – Research Report) on March 13 and
- 03/16/2020
|
Analysts Offer Insights on Healthcare Companies: Galmed Pharmaceuticals (GLMD) and MyoKardia (MYOK)
- There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Galmed Pharmaceuticals (GLMD) and MyoKardia (MYOK) with
- 03/16/2020
|
Analysts Offer Insights on Healthcare Companies: Galmed Pharmaceuticals (NASDAQ: GLMD) and MyoKardia (NASDAQ: MYOK)
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Galmed Pharmaceuticals (
GLMD
–
Research Report
) and MyoKardia (
MYOK
–
Research Report
) with bullish sentiments.
Galmed Pharmaceuticals (GLMD)
In a repo
- 03/16/2020
|
Analysts Offer Insights on Healthcare Companies: Sientra (SIEN), Nabriva (NBRV) and Galmed Pharmaceuticals (GLMD)
- There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Sientra (SIEN), Nabriva (NBRV) and Galmed Pharmaceuticals
- 03/13/2020
|
Analysts Offer Insights on Healthcare Companies: Sientra (NASDAQ: SIEN), Nabriva (NASDAQ: NBRV) and Galmed Pharmaceuticals (NASDAQ: GLMD)
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Sientra (
SIEN
–
Research Report
), Nabriva (
NBRV
–
Research Report
) and Galmed Pharmaceuticals (
GLMD
–
Research Report
) with bullish sentiments.
Sient
- 03/13/2020
|
Stifel Maintains Buy on Galmed Pharmaceuticals, Lowers Price Target to $25
|
The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 11)
Bicycle Therapeutics...
- 03/12/2020
|
Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2019 Financial Results
- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in a Phase 3 clinical trial for the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis provides today a business update and reports financial results for the three and twelve months ended December 31, 2019. The Company will host a conference call and webcast at 08:30 ET today.
- 03/12/2020
|
Earnings Scheduled For March 12, 2020
- Companies Reporting Before The Bell Dollar General Corporation (NYSE: DG ) is projected to report quarterly earnings at $2.02 per share on revenue of $7.15 billion. Genesco Inc. (NYSE: GCO ) is estimated to report quarterly earnings at $2.75 per share on revenue of $680.43 million. BEST Inc. (NYSE: BEST ) is expected to report quarterly earnings at $0.42 per share on revenue of $10.90 billion. 58.com Inc. (NYSE: WUBA ) is projected to report quarterly earnings at $0.80 per share on revenue of $587.26 million. Genesis Healthcare, Inc. (NYSE: GEN ) is estimated to report quarterly loss at $0.11 per share on revenue of $1.09 billion. Spartan Motors, Inc. (NASDAQ: SPAR ) is expected to report quarterly earnings at $0.36 per share on revenue of $230.00 million. Party City Holdco Inc. (NYSE: PRTY ) is estimated to report quarterly earnings at $0.88 per share on revenue of $748.82 million. RadNet, Inc. (NASDAQ: RDNT ) is projected to report quarterly earnings at $0.15 per share on revenue of $294.16 million.
- 03/12/2020
|
Galmed Pharmaceuticals Q4 EPS $(0.39) Misses $(0.34) Estimate
|
The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 10) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) Aytu Bioscience Inc (NASDAQ: AYTU ) ( announced a deal to distribute COVID-19 test) Centogene NV (NASDAQ: CNTG ) Forty Seven Inc (NASDAQ: FTSV ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 10) Accelerate Diagnostics Inc (NASDAQ: AXDX ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Akari Therapeutics PLC (NASDAQ: AKTX ) Akcea Therapeutics Inc (NASDAQ: AKCA ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) Alkermes Plc (NASDAQ: ALKS ) Allena Pharmaceuticals Inc (NASDAQ: ALNA ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) AngioDynamics, Inc. (NASDAQ: ANGO ) ANI Pharmaceuticals Inc (NASDAQ: ANIP ) Anixa Biosciences Inc (NASDAQ: ANIX ) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Aptinyx Inc (NASDAQ: APTX ) Assertio Therapeutics Inc (NASDAQ: ASRT ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Atossa Therapeutics Inc (NASDAQ: ATOS ) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) AxoGen, Inc Common Stock (NASDAQ: AXGN ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) Bausch Health Companies Inc (NYSE: BHC ) Bellicum Pharmaceuticals Inc (NASDAQ: BLCM ) BENITEC BIOPHAR/S ADR (NASDAQ: BNTC ) BioLife Solutions Inc (NASDAQ: BLFS ) bluebird bio Inc (NASDAQ: BLUE ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Capricor Therapeutics Inc (NASDAQ: CAPR ) Celcuity Inc (NASDAQ: CELC ) Cerecor Inc (NASDAQ: CERC ) Chembio Diagnostics Inc (NASDAQ: CEMI ) Eiger Biopharmaceuticals Inc (NASDAQ: EIGR ) Enochian Biosciences Inc (NASDAQ: ENOB ) Entasis Therapeutics Holdings Inc (NASDAQ: ETTX ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Evolus Inc (NASDAQ: EOLS ) Exicure Inc (NASDAQ: XCUR ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Gossamer Bio Inc (NASDAQ: GOSS ) Gritstone Oncology Inc (NASDAQ: GRTS ) GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) Heron Therapeutics Inc (NASDAQ: HRTX ) Incyte Corporation (NASDAQ: INCY ) INmune Bio Inc (NASDAQ: INMB ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) Jaguar Health Inc (NASDAQ: JAGX ) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) Kura Oncology Inc (NASDAQ: KURA ) Lantheus Holdings Inc (NASDAQ: LNTH ) TapImmune Inc.
- 03/11/2020
|
The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues
- Biotech stocks rebounded in the week ended March 6, recovering from the previous week's steep sell-off.
The week was light on news flow, barring some smid-cap earnings and...
- 03/08/2020
|
Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2019 Financial Results and Provide Business Update on Thursday March 12
- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in Phase 3 clinical trial for the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis announced today that it will host a conference call and webcast on Thursday, March 12, 2020, to provide an update on current developments with respect to its clinical programs for Aramchol™ and to discuss financial results for the quarter and year ended December 31, 2019.
- 03/05/2020
|
BioCryst Pharmaceuticals (BCRX) in Focus: Stock Moves 8.5% Higher
- BioCryst Pharmaceuticals (BCRX) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
- 02/28/2020
|
Analysts Offer Insights on Healthcare Companies: Irhythm Technologies (IRTC), Madrigal Pharmaceuticals (MDGL) and Atara Biotherapeutics (ATRA)
- There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Irhythm Technologies (IRTC), Madrigal Pharmaceuticals
- 02/28/2020
|
140 Biggest Movers From Yesterday
|
Analysts Offer Insights on Healthcare Companies: Theratechnologies (THTX), Intercept Pharma (ICPT) and Xencor (XNCR)
- There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Theratechnologies (THTX), Intercept Pharma (ICPT) and
- 02/26/2020
|
Analysts Offer Insights on Healthcare Companies: Theratechnologies (NASDAQ: THTX), Intercept Pharma (NASDAQ: ICPT) and Xencor (NASDAQ: XNCR)
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Theratechnologies (
THTX
–
Research Report
), Intercept Pharma (
ICPT
–
Research Report
) and Xencor (
XNCR
–
Research Report
) with bullish sentiments.
Th
- 02/26/2020
|
NASH: The Second Wave
- Although the first wave (the companies with drugs at Phase-3) is already at the finish line, the effectiveness indicators of these drugs are far from being stro
- 02/20/2020
|
Knoll Capital Management, LP Buys Exicure Inc, Entera Bio, Abeona Therapeutics Inc, Sells ...
|
13 Key NASH Drug Candidates To Watch For In A Potential $30-Billion Market
- Non-alcoholic steatohepatitis, or NASH, is a metabolic disorder caused by a buildup of fat in the liver, leading to liver inflammation and damage. It belongs to a group of conditions called non-alcoholic ...
- 02/05/2020
|
68 Biggest Movers From Yesterday
- Gainers
Myomo Inc (NYSE: MYO) shares climbed 114.7% to close at $12.99 on Tuesday after the company's MyoPro was approved for reimbursement by German health insurer BARMER....
- 02/05/2020
|
's Top Upgrades, Downgrades For February 4, 2020
- Upgrades
For Green Dot Corp (NYSE: GDOT), Citigroup upgraded the stock from Sell to Neutral. For the third quarter, Green Dot had an EPS of $0.20, compared to year...
- 02/04/2020
|
Craig-Hallum Initiates Coverage On Galmed Pharmaceuticals with Buy Rating, Announces $18 Price Target
|
Cantor Fitzgerald Assumes Galmed Pharmaceuticals at Overweight, Lowers Price Target To $14
|
The Daily Biotech Pulse: Novartis Earnings, Hepion's NASH Candidate Beats Rival Drugs, Annovis Bio To Debut
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 28) 10X Genomics Inc (NASDAQ: TXG ) Acceleron Pharma Inc (NASDAQ: XLRN ) ( announced positive Phase 2 results for its pulmonary hypertension drug) Agile Therapeutics Inc (NASDAQ: AGRX ) AtriCure Inc. (NASDAQ: ATRC ) Avenue Therapeutics Inc (NASDAQ: ATXI ) Catalent Inc (NYSE: CTLT ) Hologic, Inc. (NASDAQ: HOLX ) Insulet Corporation (NASDAQ: PODD ) Johnson & Johnson (NYSE: JNJ ) NeoGenomics, Inc. (NASDAQ: NEO ) Nevro Corp (NYSE: NVRO ) Profound Medical Corp (NASDAQ: PROF ) Quest Diagnostics Inc (NYSE: DGX ) Rapt Therapeutics Inc (NASDAQ: RAPT ) Satsuma Pharmaceuticals Inc (NASDAQ: STSA ) SI-Bone Inc (NASDAQ: SIBN ) TFF Pharmaceuticals Inc (NASDAQ: TFFP ) Y-mAbs Therapeutics, Inc (NASDAQ: YMAB )(H.C. Wainwright reiterated a Buy rating on shares) Down In The Dumps (Biotech Stocks Hitting 52-week lows on Jan. 28) Correvio Pharma Corp (NASDAQ: CORV ) Endologix, Inc. (NASDAQ: ELGX ) Galectin Therapeutics Inc. (NASDAQ: GALT ) Heat Biologics Inc (NASDAQ: HTBX ) Neuronetics Inc (NASDAQ: STIM ) REDHILL BIOPHAR/S ADR (NASDAQ: RDHL ) Salarius Pharmaceuticals Inc (NASDAQ: SLRX ) X4 Pharmaceuticals Inc (NASDAQ: XFOR ) VIVUS, Inc. (NASDAQ: VVUS ) Stocks In Focus Novartis Q4 Sales, Core Income Rise, Guides to Sales, Earnings Growth Novartis AG (NYSE: NVS ) said its fourth-quarter sales rose 8% to $12.403 million, up 8% year-over-year.
- 01/29/2020
|
P.a.w. Capital Corp Buys OptimizeRx Corp, Aptose Biosciences Inc, Orchard Therapeutics PLC, ...
|
Madrigal: Beyond NASH
- After the robust Phase 2 NASH data for resmetirom, Madrigal commenced its Phase 3 trial earlier this year. There is another upcoming Phase 3 investigation to st
- 01/14/2020
|
Is Galmed Pharmaceuticals Ltd.'s (NASDAQ:GLMD) CEO Overpaid Relative To Its Peers?
- Allen Baharaff has been the CEO of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) since 2012. This analysis aims first to...
- 01/03/2020
|
Do Hedge Funds Love Galmed Pharmaceuticals Ltd (GLMD)?
- Based on the fact that hedge funds have collectively under-performed the market for several years, it would be easy to assume that their stock picks simply aren't very good. However, our research shows this not to be the case. In fact, when it comes to their very top picks collectively, they show a strong ability […]
- 12/15/2019
|
80 Biggest Movers From Yesterday
|
48 Stocks Moving In Monday's Mid-Day Session
|
72 Biggest Movers From Yesterday
|
Top Ranked Momentum Stocks to Buy for December 4th
- Top Ranked Momentum Stocks to Buy for December 4th
- 12/04/2019
|
38 Stocks Moving In Wednesday's Mid-Day Session
|
75 Biggest Movers From Yesterday
|
44 Stocks Moving In Monday's Mid-Day Session
|
NASH Scorecard Year to Date: The Winners and the Losers
- NASH sees a highly rewarding market with candidates of blockbuster potential. Let us take a look at the hits and misses in this space so far this year.
- 11/29/2019
|
Galmed Pharmaceuticals Ltd (GLMD) CEO Allen Baharaff on Q3 2019 Results - Earnings Call Transcript
|
Edited Transcript of GLMD earnings conference call or presentation 6-Nov-19 1:30pm GMT
- Q3 2019 Galmed Pharmaceuticals Ltd Earnings Call
- 11/09/2019
|
Galmed Pharmaceuticals Provides Business Update and Reports Third Quarter 2019 Financial Results
- - Conference Call and Webcast Today at 8:30 a.m. EST / 5:30 a.m. PST - TEL AVIV, Israel , Nov. 6, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), ...
- 11/06/2019
|
Galmed Pharmaceuticals Q3 EPS $(0.21) Beats $(0.29) Estimate
|
Such Is Life: How Galmed Pharmaceuticals (NASDAQ:GLMD) Shareholders Saw Their Shares Drop 60%
- This week we saw the Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) share price climb by 22%. But that isn't much...
- 11/04/2019
|
58 Biggest Movers From Friday
|
50 Stocks Moving In Friday's Mid-Day Session
|
Galmed Pharmaceuticals to Present New Data on Aramchol Effect on Glucose Metabolism, MoA and Clinical Results at AASLD 2019
- TEL AVIV, Israel, Oct. 31, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in Phase 3/4 clinical trial for the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis announced today that it will present new data at The Liver Meeting®, the annual meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, November 8-12, 2019. This new pre-clinical data elucidates the mechanism by which Aramchol affects glucose metabolism in the liver that resulted in a reduction of HbA1C in patients in the Company's Phase IIb trial. The data suggests that Aramchol improves liver glucose homeostasis in patients and murine models.
- 10/31/2019
|
Galmed Pharmaceuticals to Report Third Quarter 2019 Financial Results and Provide Business Update on Wednesday, November 6
- TEL AVIV, Israel , Oct. 30, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development ...
- 10/30/2019
|
The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout
- The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 10.) The Medicines Company (NASDAQ: MDCO ) Ra Pharmaceuticals Inc (NASDAQ: RARX ) ( announced a deal to be bought by Belgium's UCB) Down In The Dumps (Biotech stocks that hit 52-week lows Oct. 10.) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADMP ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Aileron Therapeutics Inc (NASDAQ: ALRN ) Alkermes Plc (NASDAQ: ALKS ) Atreca Inc (NASDAQ: BCEL ) AzurRx BioPharma Inc (NASDAQ: AZRX ) (announced CEO departure) BioNano Genomics Inc (NASDAQ: BNGO ) BioTelemetry Inc (NASDAQ: BEAT ) Cellectis SA (NASDAQ: CLLS ) Cerus Corporation (NASDAQ: CERS ) Chimerix Inc (NASDAQ: CMRX ) Citius Pharmaceuticals Inc (NASDAQ: CTXR ) Clovis Oncology Inc (NASDAQ: CLVS ) Cocrystal Pharma Inc (NASDAQ: COCP ) CymaBay Therapeutics Inc (NASDAQ: CBAY ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI ) Dermira Inc (NASDAQ: DERM ) Diffusion Pharmaceuticals Inc (NASDAQ: DFFN ) Enochian Biosciences Inc (NASDAQ: ENOB ) Galmed Pharmaceuticals Ltd (NASDAQ: GLMD ) Gemphire Therapeutics Inc (NASDAQ: GEMP ) Genprex Inc (NASDAQ: GNPX ) Gossamer Bio Inc (NASDAQ: GOSS ) Helius Medical Technologies Inc (NASDAQ: HSDT ) Homology Medicines Inc (NASDAQ: FIXX ) Hoth Therapeutics Inc (NASDAQ: HOTH ) Jaguar Health Inc (NASDAQ: JAGX ) (announced plans to explore options to license Mytesi in China) Meridian Bioscience, Inc. (NASDAQ: VIVO ) MOTIF BIO PLC/S ADR (NASDAQ: MTFB ) MOTIF BIO PLC/S ADR (: MTFB) Novus Therapeutics Inc (NASDAQ: NVUS ) Obalon Therapeutics Inc (NASDAQ: OBLN ) Onconova Therapeutics Inc (NASDAQ: ONTX ) Orgenesis Inc (NASDAQ: ORGS ) PAVmed Inc (NASDAQ: PAVM ) Precision BioSciences …
- 10/11/2019
|
Stocks That Hit 52-Week Lows On Thursday
|
The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 9) Aprea Therapeutics Inc (NASDAQ: APRE ) (IPOed Oct. 3) Down In The Dumps (Biotech stocks hitting 52-week lows on Oct. 9) ABIOMED, Inc. (NASDAQ: ABMD ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Albireo Pharma Inc (NASDAQ: ALBO ) Arbutus Biopharma Corp (NASDAQ: ABUS ) Assembly Biosciences Inc (NASDAQ: ASMB ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) BioNano Genomics Inc (NASDAQ: BNGO ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Caladrius Biosciences Inc (NASDAQ: CLBS ) Calithera Biosciences Inc (NASDAQ: CALA ) Citius Pharmaceuticals Inc (NASDAQ: CTXR ) Clovis Oncology Inc (NASDAQ: CLVS ) CymaBay Therapeutics Inc (NASDAQ: CBAY ) CytomX Therapeutics Inc (NASDAQ: CTMX ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI ) Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) Erytech Pharma SA (NASDAQ: ERYP ) Exagen Inc (NASDAQ: XGN ) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Galmed Pharmaceuticals Ltd (NASDAQ: GLMD ) Gossamer Bio Inc (NASDAQ: GOSS ) Heat Biologics Inc (NASDAQ: HTBX ) Homology Medicines Inc (NASDAQ: FIXX ) INmune Bio Inc (NASDAQ: INMB ) Intellia Therapeutics Inc (NASDAQ: …
- 10/10/2019
|
The Daily Biotech Pulse: IPOs, Puma's Breast Cancer Drug Gets Label Expansion, Buyout Offer For Organovo
|
Stocks That Hit 52-Week Lows On Wednesday
|
Galmed Pharmaceuticals Initiated ARMOR, a Phase 3/4 Registrational Study of Aramchol in Subjects With NASH and Fibrosis
- TEL AVIV, Israel, Sept. 26, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol, an oral therapy for the treatment of nonalcoholic steatohepatitis ("NASH") and fibrosis, announced today the initiation of its Phase 3/4 ARMOR clinical study to evaluate the efficacy and safety of Aramchol in subjects with NASH and fibrosis. This double-blind, placebo-controlled, global study will be conducted in approximately 185 sites in the U.S., Europe, Latin America and Asia. The ARMOR study will evaluate the efficacy and safety of Aramchol in subjects with NASH and fibrosis stages 2-3 who are overweight or obese and have prediabetes or type 2 diabetes. A total of 2000 subjects will be randomized 2:1 to receive Aramchol 300mg BID or matching placebo.
- 09/26/2019
|
Should You Buy Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) For This Reason?
- Trailing twelve-month data shows us that Galmed Pharmaceuticals Ltd.'s (NASDAQ:GLMD) earnings loss has accumulated to...
- 09/19/2019
|
70 Biggest Movers From Yesterday
|
Galmed Pharmaceuticals Q2 EPS $(0.2) Beats $(0.22) Estimate
|
The Week Ahead In Biotech: Focus On Earnings Deluge, Mid-Year Clinical Trial Readouts
|
Ibex Investors LLC Buys Strategic Education Inc, Redhill Biopharma, Radware, Sells SolarEdge ...
|
Benzinga's Top Upgrades, Downgrades For July 22, 2019
|
60 Biggest Movers From Friday
|
40 Stocks Moving In Friday's Mid-Day Session
|
Galmed Pharmaceuticals Q1 EPS $(0.17) Beats $(0.2) Estimate
|
Galmed Pharma Says it Has Reached an Agreement with the FDA on Key Aspects of its Phase 3/4 ARMOR Study
|
Galmed And Aramchol In NASH, And The Market Assessment
|
56 Stocks Moving In Thursday's Mid-Day Session
|
Galmed Pharmaceuticals Q4 EPS $(0.18) Misses $(0.13) Estimate
|
Galmed Reports 'Positive' Results From Pharmacokinetic Split Dose Study Of Aramchol
|
The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings, IPOs
|
Galmed And Aramchol In NASH: Moving On Higher
|
52 Biggest Movers From Yesterday
|
Galmed Pharmaceuticals shares are trading up 10.5% after B. Riley initiated coverage on the stock with a Buy rating and a price target of $28.
|
Ibex Investors LLC Buys Silicom, Lithium Americas Corp, General Motors Co, Sells Mellanox ...
|
Galmed: A Deep-Dive Analysis Of The ARREST Trial
|
Recent Analysis Shows COUPA SOFTWARE, Galmed Pharmaceuticals, Sunworks, Murphy, Diversicare ...
|
Galmed Announces Phase 2 Data for Aramchol in NASH Presented During Late-Breaking Abstract Oral Session of The Liver Meeting 2018
|
5 Stocks Moving In Monday's After-Hours Session
|
The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs
|
Galmed Pharmaceuticals Q3 EPS $(0.05) Beats $(0.14) Estimate, Sales $1.5M Beat $140K Estimate
|
The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs
|
71 Biggest Movers From Friday
|
Now Corbus Joins The NASH Fray
|
Expected Value Investing: The Case Against Galmed
|
68' Capital Management, LLC Buys The Kroger Co, Alnylam Pharmaceuticals Inc, Adient PLC, ...
|
Galmed Pharmaceuticals: Buy This NASH Play?
|
68' Capital Management, LLC Buys The Kroger Co, Alnylam Pharmaceuticals Inc, Adient PLC, ...
|
Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q2 2018 Results - Earnings Call Transcript
|
Galmed Pharmaceuticals Q2 EPS $(0.17) Misses $(0.16) Estimate, Sales $270K Inline
|
Galmed Pharmaceuticals: High Price Targets And High Hopes Lead To High Levels Of Disappointment
|
Raymond James Initiates Coverage On Galmed Pharmaceuticals with Outperform Rating, Announces $26 Price Target
|
38 Biggest Movers From Friday
|
Rounds Report: Galmed Rallied Subsequent To The Overweight Rating Of Dr. Elemer Piros
|
Galmed Notches Second Bullish Rating On Aramchol Opportunity
|
30 Stocks Moving In Thursday's Mid-Day Session
|
Galmed Shares Gain 12.8% After Hours Following Cantor Fitzgerald Initiation At Overweight With $59 PT Compared With Closing Price Of $10.55
|
Galmed Pharmaceuticals: Strong Fundamentals Powering A NASH Innovator
|
Galmed Pharmaceuticals Prices 5M Share Public Offering of Ordinary Shares @$15/Share
|
21 Stocks Moving In Tuesday's Pre-Market Session
|
Galmed Pharmaceuticals Announces Proposed Offering of $75M
|
40 Biggest Movers From Yesterday
|
Galmed Pharmaceuticals: Is The Pop Justified?
|
Maxim Group Maintains Buy on Galmed Pharmaceuticals, Raises Price Target to $30
|
Galmed to release mid-stage data on NASH candidate Aramchol this morning; shares up 60% premarket
|
